LEU — Centrus Energy Corp.
Price when we picked it (Jul 23, 2026)
$170.00
Target: $264.73 (+55.7%)
P/E Ratio
61.8
P/E Forward
43.1
Dividend
—
Market Cap
$3.36B
EPS
$2.75
Consensus
Buy
What they do
Centrus Energy Corp. (NYSE American: LEU) is a US nuclear fuel company. Its core business is uranium enrichment: taking natural uranium and raising the concentration of the U-235 isotope to the level a reactor needs to generate electricity. Headquartered in Bethesda, Maryland; production plant in Piketon, Ohio.
Two segments:
**
- LEU (Low-Enriched Uranium)** — sells standard nuclear fuel to electric utilities that operate nuclear plants in the US and worldwide. Historically bought some material from third parties (including Russia) and resold it; now rebuilding its own domestic enrichment capacity.
**
- HALEU (High-Assay Low-Enriched Uranium) — the strategic crown jewel. Uranium enriched to higher purity (up to ~20%), the fuel required by small modular reactors (SMRs) and next-generation advanced reactors. Centrus is the only NRC-licensed facility** to produce HALEU in the US, at its Piketon, Ohio plant.
Why this matters: after the invasion of Ukraine, the US banned imports of Russian enriched uranium (Russia controlled ~40–50% of the global enrichment market). That left a massive gap in the Western nuclear supply chain. Centrus is the US government's bet on restoring domestic production: it received a Department of Energy (DOE) order worth ~$900M and holds a pipeline of signed orders worth ~$3.9 billion through 2040.
Leadership: CEO Amir Vexler. The company does NOT pay a dividend — it reinvests everything in expanding enrichment capacity. Q1 2026: revenue $76.7M, EPS $0.45. The stock is highly volatile: it fell from ~$189 to ~$165 after a Q1 that came in below expectations.
Why we like it
Buying LEU at $170.00 means REINFORCING (we'd already held it since June 8 at $167.07) the ONLY American-owned producer able to enrich uranium in the U.S., right when the country is legally required to stop depending on Russia for its nuclear fuel — and now with the government's $900M contract firmly signed. Specific reasons:
- Strategic HALEU monopoly: Centrus is the only facility licensed to produce the fuel (HALEU) that next-generation nuclear reactors need. Without that fuel, the entire SMR industry can't get going —and Centrus is the bottleneck—.
- Geopolitical tailwind: the U.S. banned Russian enriched uranium; Russia controlled ~40-50% of the global market. Rebuilding Western capacity is now a national-security priority, with federal money behind it.
- Government backing: a DOE order of ~$900M + a backlog of ~$3.9 billion in orders through 2040 —very long-term revenue visibility—.
- Nuclear renaissance: electricity demand from AI data centers is pushing the tech giants (Microsoft, Amazon, Google) to sign nuclear deals; more reactors = more demand for enriched fuel.
- Capacity catalyst: every new centrifuge cascade Centrus brings online in Piketon multiplies its production capacity. Analysts: 'Moderate Buy', average target ~$268 (~+60%).
Key Risk
Risks:
- Very high valuation — #1: at ~58x earnings, the price already bakes in a lot of optimism. If capacity expansion is delayed or HALEU orders arrive more slowly, the stock can correct sharply (as it already did: -13% after a weak quarter).
- No dividend: it is 100% a growth bet; you receive no income while you wait.
- Government dependency: a large part of the investment case depends on DOE funding and contracts; a change in political priorities or federal budget hits directly.
- Technical execution: enriching uranium is among the most complex and regulated processes in existence; any operational, licensing (NRC) or safety issue can halt production.
- Extreme volatility: it is a 'theme stock' that moves with nuclear energy headlines, not stable fundamentals — not for the faint of heart.
- SMR demand still early: next-generation reactors are still being built; if their deployment is delayed by years, HALEU demand takes longer to materialize.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked LEU on Jun 8, 2026 at $167.07.
Full Research
Centrus Energy (LEU) — Full Research
Price: $167.07 | Price vs. profit (TTM): ~58.6x | Div Yield: 0% | Market Cap: ~$3.25B USD
What is Centrus?
The only US-owned company that enriches uranium — the nuclear fuel — on US soil. Headquartered in Bethesda, Maryland; plant in Piketon, Ohio. Does NOT pay a dividend: reinvests everything in capacity.
2 Segments
| Segment | What it is | Note |
|---|---|---|
| LEU (low enrichment) | Standard nuclear fuel for power plants | Rebuilding domestic production |
| HALEU (high enrichment) | Fuel for next-generation reactors (SMRs) | ONLY NRC-licensed plant in the US |
The Geopolitical Case
- After the Ukraine invasion, the US banned imports of Russian enriched uranium.
- Russia controlled ~40–50% of the global enrichment market.
- Centrus = the US bet on restoring domestic production.
- DOE order: ~$900M | Pipeline of signed orders: ~$3.9 billion through 2040.
Q1 2026
| Metric | Q1 2026 |
|---|---|
| Revenue | $76.7M |
| EPS | $0.45 |
| Stock reaction | -13% (dropped from ~$189 to ~$165, quarter below expectations) |
Leadership
- CEO: Amir Vexler.
- Dividend: $0 (100% reinvestment).
Anchor Fact
There is ONE single company with US government permission to make the fuel that next-generation nuclear reactors need — and it's Centrus. For decades, this fuel came mostly from Russia. When the US banned purchases from Russia after the war, a giant gap opened up: someone had to produce it at home. Centrus is that company, and the Department of Energy itself signed it an order worth ~$900 million to do so.
Top 5 Risks
- Very high valuation (~58x) — the price already prices in a lot of optimism
- No dividend — 100% growth bet
- Government dependency — the case depends on DOE funding
- Technical + regulatory execution (NRC) — enriching uranium is extremely complex
- SMR demand still early — new reactors take time to be deployed
Analyst Consensus
- Rating: Moderate Buy
- Average target: ~$268 (~+60% from $167.07)
The Thesis in One Line
The only US producer of enriched nuclear fuel, irreplaceable for US energy independence right when the country is banned from buying it from Russia.
Research date: Jun 8, 2026 | Next review: Dec 2026
This is not financial advice.
More picks in Energy
See all Energy picks →This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.